Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PDE2A | O00408 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.32 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2206586 | 0.79 | HTT (0.62) | HTTSMN1; SMN2PRKCIMAPTPKM | |
| SCHEMBL3539246 | 0.76 | PARP10 (0.48) | PDE2AAKR1C3AKR1C2MAPTHSD17B10 | |
| SCHEMBL2636947 | 0.73 | KDM1A (0.46) | PDE2AKDM1AMAPTHSD17B10 | |
| SCHEMBL2636949 | 0.73 | KDM1A (0.46) | PDE2AKDM1AMAPTHSD17B10 | |
| SCHEMBL1970199 | 0.72 | PDE2A (0.52) | PDE2AKDM1AAKR1C3AKR1C2HAO1 | |
| SCHEMBL353975 | 0.72 | HTT (0.50) | HTTSMN1; SMN2 | |
| SCHEMBL469734 | 0.69 | LMNA (0.55) | HTTSMN1; SMN2MAPTPKMHSD17B10 | |
| SCHEMBL14018619 | 0.69 | HTT (0.58) | HTTSMN1; SMN2MAPTPKMHSD17B10 | |
| SCHEMBL21588074 | 0.69 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL1194001 | 0.68 | TSHR (0.60) | SMN1; SMN2AKR1C3AKR1C2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709509-B2 | Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7709509-B2 | Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7709509-B2 | Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| CN-100582104-C | Oxadiazolone derivatives as PPAR delta agonists | SANOFI AVENTIS DEUTSCHLAND | 2010-01-20 | — | — | CN | disclosed |
| EP-2083006-A1 | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2009-07-29 | — | — | EP | disclosed |
| EP-2083006-A1 | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2009-07-29 | — | — | EP | disclosed |
| EP-1740583-B1 | OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-01 | — | — | EP | disclosed |
| EP-1740583-B1 | OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-20080262052-A1 | METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080262052-A1 | METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080262052-A1 | METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080255212-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255212-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255212-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20070179191-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | disclosed |
| US-20070179191-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | disclosed |
| US-20070179191-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | disclosed |
| CN-1938300-A | Oxadiazolone derivatives as PPAR delta agonists | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-03-28 | — | — | CN | disclosed |
| EP-1740583-A1 | OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005097786-A1 | OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179191-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS | PPARD, PPARA, PPARG | HTT 2065/4885SMN1; SMN2 410/4885PDE2A 921/4885 |
| US-20080255212-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | PPARD, PPARG, PPARA | HTT 2444/4885SMN1; SMN2 404/4885PDE2A 1445/4885 |
| US-20080262052-A1 | METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | PPARD, PPARG, PPARA | HTT 1957/4885SMN1; SMN2 325/4885PDE2A 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.